Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Incannex Healthcare (IXHL) EBITDA (2023 - 2025)

Incannex Healthcare (IXHL) has disclosed EBITDA for 3 consecutive years, with -$6.8 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 7.93% to -$6.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$48.3 million through Dec 2025, down 98.17% year-over-year, with the annual reading at -$46.7 million for FY2025, 151.94% down from the prior year.
  • EBITDA hit -$6.8 million in Q4 2025 for Incannex Healthcare, down from -$6.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$1.2 million in Q3 2023 to a low of -$31.3 million in Q2 2025.
  • Historically, EBITDA has averaged -$7.8 million across 3 years, with a median of -$6.2 million in 2024.
  • Biggest YoY gain for EBITDA was 40.8% in 2025; the steepest drop was 409.45% in 2025.
  • Year by year, EBITDA stood at -$4.3 million in 2023, then tumbled by 46.22% to -$6.3 million in 2024, then dropped by 7.93% to -$6.8 million in 2025.
  • Business Quant data shows EBITDA for IXHL at -$6.8 million in Q4 2025, -$6.2 million in Q3 2025, and -$31.3 million in Q2 2025.